The LancetOriginal article
[Articles] Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial
Phase 3positiveDeucrictibantPositive
AI Analysis
Summary
Oral deucrictibant demonstrated superior efficacy over placebo in a phase 3 trial for hereditary angioedema attacks, showing faster symptom relief and good tolerability. Results support potential development as the first oral bradykinin B2 receptor antagonist for bradykinin-mediated angioedema treatment.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Oral deucrictibant provided faster times to symptom relief than placebo and was generally well tolerated in phase 3 multicentre randomised double-blind placebo-controlled crossover trial
Importance:7/10
Sentiment:
0.85
Phase 3Hereditary AngioedemaOral TreatmentBradykinin B2 Receptor AntagonistClinical Trial
Read the original article
Published by The Lancet on October 8, 2026 10:30 PM